VisionGate, Inc., a Phoenix, AZ-based biotech company dedicated to early disease detection and prevention of lung cancer, received an investment from Trinnovate Ventures, a subsidiary of Blue Cross Blue Shield of Arizona.
The amount of the deal was not disclosed.
The company intends to use the funds to advance and commercialize its products.
Led by Scarlett Spring, MBA – President, Alan C. Nelson, PhD – Founder, Chairman & CEO, Chief Medical Officer Dr. Javier Zulueta, Michael G. Meyer, MS – Chief Technical Officer, VisionGate provides LuCED, a physician-ordered, take-home sputum test to aid physicians in the early detection of lung cancer.
This test is processed on an automated 3D cell imaging platform, called Cell-CT, similar in principle to taking a CT scan of individual cells, but using visible light without harmful radiation.
The company also has exclusive rights to Iloprost, which is a drug focused on stopping the advancement of the disease.